Federated Hermes, Inc. Arcellx, Inc. Transaction History
Federated Hermes, Inc.
- $43 Billion
- Q4 2024
A detailed history of Federated Hermes, Inc. transactions in Arcellx, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 156,094 shares of ACLX stock, worth $9.94 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
156,094
Previous 64,664
141.39%
Holding current value
$9.94 Million
Previous $5.4 Million
120.15%
% of portfolio
0.03%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding ACLX
# of Institutions
227Shares Held
45MCall Options Held
450KPut Options Held
647K-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$279 Million12.7% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$239 Million20.37% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$224 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.48MShares$222 Million8.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.33MShares$212 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.79B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...